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Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxi-
dase antibodies. To investigate a possible role of anti-neutrophil cytoplas-
mic antibodies directed against myeloperoxidase (MPO-ANCA) in gb-
merulonephritis, we prepared anti-rat MPO antiserum by immunization of
rat MPO into a rabbit. Then we administered anti-rat MPO antiserum
(group 1) or normal rabbit serum (NRS) (group 2) into rats before
injection of nephrotoxic serum (NTS), which induced nephrotoxic serum
nephritis (NTN). Other groups of rats received either anti-rat MPO
anti-serum (group 3) or NRS (group 4) before injection of NRS but not
NTS. Rats in group I and group 2 were sacrificed at either 3 hours, 15
hours, or 14 days after NTS injection. Rats in group 3 and group 4 were
sacrificed at 15 hours after the last NRS injection. By light microscopy, in
rats with NTN sacrificed at 3 hours, counts of polymorphonuclear
leukocytes (PMN) per gbomerulus were 21.6 3.5 in group 1 and 8.4 1.7
in group 2 (P < 0.01). At 15 hours, massive glomerular fibrin deposits were
observed in group 1 rats (fibrin score, 131 8), but not in group 2 rats
(fibrin score, 27 21; P < 0.01). By direct immunofluorescence micros-
copy, rat MPO was found along gbomerular capillary walls more intensely
in group 1 rats than in group 2 rats. No pathological alterations were found
in group 3 and group 4 rats. Further, renal elution studies revealed that
eluted rabbit IgG contained anti-rat MPO antibodies in group 1 rats but
not in group 3 rats. These results suggest that the anti-MPO antibodies are
directly involved in the more severe glomerular lesions in group I rats via
interactions with MPO itself or activation of PMN, which release various
kinds of mediators including MPO.
It has been shown that anti-neutrophil cytoplasmic antibodies
(ANCA) are frequently detected in sera from patients with
Wegener's granulomatosis, microscopic polyarteritis nodosa (PN)
and idiopathic pauci-immune crescentic glomerulonephritis
(CGN) [1—5]. ANCA are divided into two major subsets according
to immunofluorescence findings: cytoplasmic (C)-ANCA and
perinuclear (P)-ANCA. C-ANCA are usually specific for 29 kD
serine proteinase; proteinase-3, and P-ANCA are usually specific
for myeloperoxidase (MPO).
Among ANCA, MPO-ANCA directed against myeloperoxidase
is closely associated with the occurrence of idiopathic CGN and
microscopic PN [2, 3]. Although the pathogenic role of MPO-
ANCA is still unclear, a recent report on the biological activities
in vitro support the idea that it may be involved in the develop-
ment of necrotizing vascular or glomerular lesions via activation
of polymorphonuclear leukocytes (PMN) primed by proinflam-
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matory cytokines such as tumor necrosis factor-a [61.Hypotheti-
cally, ANCA related glomerulonephritis may develop after local
release of cationic lysosomal enzymes, such as MPO, which
released from PMN activated by undefined etiology [4, 5]. In the
present study, we administered rabbit anti-rat MPO antiserum
previously and induced nephrotoxic serum nephritis (NTN) by the
injection of rabbit anti-rat glomerular basement membrane
(GBM) antiserum as nephrotoxic serum (NTS) into normal
Wistar rats, so that we studied the effects of anti-MPO antibodies
on acute PMN-mediated glomerular injury. The rats that received
both anti-MPO antiserum and NTS developed acute and more
severe exudative glomerulonephritis characterized by extensive
infiltration of PMN, followed by glomerular intracapillary fibrin
thrombosis as compared to rats that received both normal rabbit
serum (NRS) and NTS.
Here we report that rabbit anti-rat MPO antibodies clearly
aggravated rat NTN. We will also discuss the possible role of
MPO and anti-MPO antibodies interactions.
Methods
Animals
Female Wistar rats weighing 150 g were purchased from
Charles River Japan (Atsugi, Kanagawa, Japan). They were fed
standard rat chow and received water ad libitum. Japanese white
rabbits were purchased from a local breeder.
MPO
Rat MPO was purified according to the method by Kariya et al
[7]. Briefly, hemoglobin-free white blood cells from bone marrow
were homogenized in 0.25 M sucrose by electric homogenizer
(Polytron, Kinematica, Luzern, Switzerland), then centrifuged at
105,000 g for 60 minutes. The precipitate was stirred with 0.5%
cethyltrimethylammonium bromide (CETAB) in 10 m potas-
sium phosphate buffer (pH 7.0) at 4°C overnight. The supernatant
of CETAB extract was collected by centrifugation and dialyzed
against 25 mivi acetate buffer containing 0.2 M NaCI (pH 4.7).
Then the dialyzed solution was applied to CM-Sephadex C-SO
column (Pharmacia Fine Chemicals, Uppsala, Sweden) and col-
lected with 0.2 to 2.0 M NaCl gradient in acetate buffer. Protein
concentration of each fraction was monitored by optical density
(OD) at 280 nm and enzyme activity was tested by guiacol as
substrate [7]. The MPO active fractions were pooled and dialyzed
against 100 m acetate buffer (pH 5.6) containing 5 mM CaCl2,
MgC12, MnC12 and 0.05% CETAB. After dialysis, crude MPO was
further purified by Con A-Sepharose column (Pharmacia Fine
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Chemicals). MPO active fractions eluted by 0.2 M Methyl-cz-D-
giucoside were pooled and concentrated. Finally, protein concen-
tration of MPO in 10 m phosphate buffer containing 0.15 M
NaC1, 0.02% CETAB and 2% glycerol was determined by BCA
protein assay reagent (Pierce, Rocklord, IL, USA) and the purity
was checked by SDS-PAGE.
Human neutrophil MPO was purchased from Calbiochem
Corp. (La Jolla, CA, USA).
Preparation of rabbit anti-rat MPO antiserum
Fifty micrograms of rat MPO in complete Freund's adjuvant
were injected intradermally into a rabbit every other week for a
total of three injections. One week later, 10 g MPO in saline was
i.v. injected. The rabbit was bled four days after the injection. An
i.v. challenge and bleeding was repeated for a total of three times.
The antisera were pooled and used for this study.
ELISA
Anti-MPO antibody was assessed by standard ELISA proce-
dure. Microtiter plate (Nunc, Roskilde, Denmark) was coated
with rat MPO at protein concentration of 5 g/ml in borate
buffered saline (pH 8.8). After saturation with 0.5% BSA in PBS,
the plates were incubated with rabbit serum diluted appropriately
with 2% BSA in PBS containing 0.05% Tween-20 (PBS-Tw).
After washing bound antibody was detected by alkaline-phos-
phatase labeled goat anti-rabbit IgG (Cappel Laboratories, West
Chester, PA, USA) and p-nitrophenyl-phosphate disodium as a
substrate. Results are expressed as OD at 405 nm. Rabbit IgG
concentration was determined by sandwich ELISA using goat
anti-rabbit IgG (Cappel Laboratories). Standard curves were
established for each assay by using purified rabbit IgG (ZYMED
Laboratories, San Francisco, CA, USA).
Isolation of pentoneal PMN
Rat PMN was prepared from peritoneal exudate cells by the
method described by Kudo, Nakamura and Koyama [8]. Saline
containing 3% casein Na was injected i.p. into rats, and after 15
hours the peritoneal exudate cells were harvested by Krebs-
Ringer phosphate buffer (KRPB, pH 7.2). The cell suspension was
centrifuged 1500 rpm for five minutes at 4°C. To remove tissue
debris, the cells were suspended in 2.47% gelatin-containing
saline for 30 minutes. Then supernatant containing cells were
centrifuged and 20 ml of 0.2% NaCI was added to cell pellets to
lyse red blood cells for 10 seconds. After the hypotonic treatment,
an equal volume of 1.6% NaC1 was added to the cell suspension
to return physiological condition immediately. The cells were
washed with KRPB repeatedly. The cells thus prepared were used
as PMN rich peritoneal cells for the preparation of cell smear by
cytocentrifuge. The purity of PMN-rich peritoneal cells was
checked by Giemsa-staining kit (Diff-Quik; Kokusaishiyaku,
Kobe, Japan). The PMN was usually more than 80% of cells
obtained by this method.
ANCA assay by immunofluorescence
The PMN was suspended in PBS to a concentration of 2 X io
cells/mi and an aliquot of 300 l was pelleted onto glass slides
using cytocentrifuge (Cytospin 3, Shandon Scientific LTD.,
Chesire, UK). The cells were fixed in absolute ethanol at —20°C
for five minutes [2]. Dried cell preparations were washed and
incubated with appropriately diluted serum samples and washed
in PBS. They were then incubated with FITC-labeled goat anti-
rabbit IgG (Cappel Laboratories). After washing, the slides were
mounted for immunofluorescence microscopy.
SDS-PAGE
SDS-PAGE was carried out according to the discontinuous
buffer procedure of Laemmli [9}. After electrophoresis the gel was
stained with Coomassie blue and the molecular weight was
estimated by molecular weight standard (Bio-Rad Laboratories,
Richmond, CA, USA). For the staining of glycoprotein, the gel
was stained with periodic acid Schiff (PAS) reagent [10].
Western blotting
After SDS-PAGE, MPO was transferred onto nitrocellulose
membrane by the method of Towbin, Staehelin and Gordon [11].
After saturation with 3% BSA in PBS, membrane was cut into
several strips and incubated with rabbit serum 1/1000 diluted with
2% BSA in PBS-Tw at 4°C overnight. After washing with PBS-Tw,
the strips were incubated with alkaline-phosphatase labeled goat
anti-rabbit IgG for an additional five hours. Then they were
washed with PBS-Tw and soaked in alkaline phosphatase buffer:
0.1 M Tris-HC1, pH 9.5 containing 0.1 M NaC1 and 5 mM MgCI2.
Finally they were developed with alkaline phosphatase buffer
containing Nitro Blue Tetrazolium, NBT and 5-bromo-4-chloro-
3-indolyl phosphate, p-toluidine salt, BCIP [12].
Labeling procedures
Goat anti-rabbit or rat IgG specific antibodies (Cappel Labo-
ratories) were labeled with alkaline phosphatase (Sigma Chemical
Co., St. Louis, MO, USA) according to the method of Engvall and
Perlmann [13]. Rabbit IgG fraction was purified from rabbit
anti-rat MPO antiserum by Protein A sepharose column (Phar-
macia Fine Chemicals), then labeled with fluorescein isothiocya-
nate (FITC) (Cappel Laboratories) by the method of Hudson and
Hay [14].
Preparation of rabbit anti-rat GBM antiserum
Rat glomeruli were isolated from Wistar rat kidneys by differ-
ential sieving method described by Spiro [15], then the isolated
glomeruli were sonicated repeatedly and washed by centrifugation
to purify GBM. The purified GBM containing 60 mg in wet weight
was emulsified in complete Freund's adjuvant and injected intra-
dermally into rabbits every other week for a total of four
injections. One week later, they were bled and sacrificed by heart
puncture. The serum anti-GBM antibody activities were tested by
indirect immunofluorescence microscopy on sections of rat kid-
ney. Sera of high responder rabbits were pooled and used as NTS
in this study. NRS was obtained from a non-immunized rabbit.
Prior to injection into rats, the antiserum was decomplemented
and absorbed with rat erythrocytes. To evaluate the anti-GBM
antibody activities in vivo, 0.1, 0.2, 0.5 or 0.7 ml of NTS was diluted
respectively with saline to 1 ml of final volume, and then they were
i.v. injected into rats.
Experimental design
Four groups of rats were treated according to the following
design. Group 1 rats received 0.8 ml of rabbit anti-rat MPO
antiserum (first i.v. injection) and 0.2 ml of NTS (second i.v.
injection), then they were sacrificed at either three hours (group
1-a, N 6), 15 hours (1-b, N = 6), or 14 days (1-c, N = 6) after
1 2 3
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Fig. 1. Biochemical characteristics of purified rat MPG. A. SDS-PAGE
(12.5%) analysis of purified rat MPO under reducing condition, lane 1, 5
Itg of human MPO; lane 2, 10 jsg of rat MPO; lane 3, molecular weight
marker protein. Numbers shown on the right side indicate molecular
weight (kD) obtained by marker protein. B. MPO activities in fluid phase
using guaiacol as substrate. Different doses of rat MPO were incubated
with 1 ml of reaction mixture containing 100 m potassium phosphate
buffer (pH 7.0), 0.33 mvi H2 02 and 33 mt guaiacol. Enzyme activities are
expressed as OD at 470 nm.
NTS injection. Group 2 rats received 0.8 ml of NRS and 0.2 ml of
NTS, and they were then sacrificed at either three hours (group
2-a, N = 6), 15 hours (2-b, N = 6), or 14 days (2-c, N = 6) after
NTS injection. Group 3 rats received 0.8 ml of rabbit anti-rat
MPO antiserum and 0.2 ml of NRS, and then they were sacrificed
at 15 hours (N = 6) after NRS injection. Group 4 rats received 0.8
ml of NRS and an additional 0.2 ml of NRS, and then they were
sacrificed at 15 hours (N = 6) after the last NRS injection.
1 2
Fig. 2. Reactivity of rabbit anti-rat MPG antibodies. A. Anti-rat MPO
ELISA. Dilution curves of pooled rabbit serum immunized with rat MPO
(.) or NRS (o). B. Rabbit anti-rat MPO antibody activities detected by
Western blotting. Five micrograms of rat MPO was subjected to SDS-
PAGE (12.5%) under reducing condition, then reactivity of 1/1000 diluted
rabbit anti-rat MPO antiserum (lane 1) or NRS (lane 2) with rat MPO
were visualized by alkaline phosphatase labeled goat anti-rabbit IgG.
Numbers shown on the right side indicate molecular weight (kD) obtained
by marker protein.
Injection of NTS or NRS for second injection was consistently
performed seven hours after first injection. All rats were bled
from abdominal aorta when they were sacrificed.
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Urinalysis
For estimation of proteinuria, urine was collected in metabolic
cages for 24 hours on day 2, day 6, day 9 and day 13 after injection
of NTS. Urinary protein was determined by the Biuret method.
Histopathology
Renal tissue was fixed in 2% paraformaldehyde/PBS and embed-
ded in parafin for light microscopy. Four micrometer sections were
stained with hematoxylin-eosin (HE), PAS and periodic acid-silver
methenamine (PASM). Counts of PMN were made in at least 15
glomeruli according to the method of Cochrane, Unanue and Dixon
[16]. The average counts per glomerulus are reported.
For immunofluorescence, the tissues were snap-frozen in liquid
nitrogen and cut to 4 m sections. Rabbit IgG, rat IgG, rat C3 and rat
fibrin/fibrinogen in the kidney sections were detected by immunoflu-
orescence with FITC labeled goat anti-rabbit IgG, anti-rat IgG,
anti-rat C3 and anti-rat fibrinogen (Cappel Laboratories).
Glomerular fibrin deposition was evaluated as follows. First the
extent of fibrin deposits of each glomerulus was graded on 50
glomeruli by four different scales: 0, absent; 1, less than 1/3; 2,
between 1/3 and 2/3 and 3, more than 2/3 of a whole glomerulus.
Finally a fibrin score per rat is reported by a sum of the number
of glomeruli that represents the respective grade times the
corresponding grade.
The presence of MPO in glomeruli was studied by direct
immunofluorescence microscopy using FITC labeled rabbit anti-
rat MPO antibodies prepared in this study. The intensity of
fluorescence was graded by the following scales: —; and,
2+. Reactivity of the FITC labeled antibodies with rat MPO was
substantiated by direct ANCA immunofluorescence test.
Elution study
Statistical analysis
Statistical analysis was performed with the Mann-Whitney U test.
Probability values greater than 5% were considered insignificant.
Results
Rat MPO
Purity of rat MPO was assesed by SDS-PAGE. In the case of
reducing conditions, the major band was demonstrated at the
position of 57 kD corresponding to large (a) subunits. Another
band, probably a small (/3) subunit was demonstrated at the
position of approximately 17 kD. In addition, several minor bands
were discernible (Fig. IA). These results were almost the same as
the previous report [7] except the position of /3 subunit. In the case
of human MPO subjected to SDS-PAGE in parallel, the a and 13
subunits were demonstrated at the position of 57 lcD and 15 kD,
respectively, which were identical to the published results [18].
When SDS-PAGE (7.5%) was performed under non-reducing
conditions without heating, rat MPO was stained at the position of
around 116 kD. Further, the glycoprotein nature was confirmed by
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Fig. 3. Immunostaining of neutrophils on
indirect immunofluorescence micmscopy. A.
Perinuclear staining of fixed PMN produced by
a 1/40 diluted rabbit serum immunized with
MPO, which is similar to so-called "P-ANCA"
fluorescence (X400). B. Negative staining of
fixed PMN produced by a 1/40 diluted NRS
(x400).
300
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Renal elution studies were performed by the method of Lerner,
I • I Glassock and Dixon [17]. Anti-GBM antibody activities and
0 2 4 6 8 10 12 14 anti-MPO antibody activities in renal eluates were tested by
indirect immunofluorescence and ELISA, respectively. Rabbit
Days after injection of NTS IgG concentration in eluates was determined by ELISA.
Fig. 4. Kinetic studies onproteinuria in group 1-c (.) and group 2-c (0) rats.
The values represent mean 1 SD. The proteinuria of group 1-c rats was
significantly higher than that of group 2-c rats on day 6 (*P < 0.05).
—S
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Fig. 5. Histological findings of glomerular lesions
in rats with NTN. A. Enhanced infiltration of
PMN in a glomerulus from a group 1-a rat
(HE, x 100). B. Limited infiltration of PMN in a
glomerulus from a group 2-a rat (HE, X 100). C.
Representative histological appearance of a
glomerulus in a group 1-b rat. Note the marked
intracapillary hyaline-like materials and
dilatation of mesangial areas (HE, X 100). D.
Representative histological appearance of a
glomerulus in a group 2-b rat. Minimal hyaline-
like materials are seen in segmental glomerular
tufts (HE, X 100).
PAS staining after SDS-PAGE (data not shown). The enzyme
activity of purified MPO have been substantiated by fluid phase
enzyme assay (Fig. 1B).
Rabbit anti-rat MPO antiserum
Anti-rat MPO antibody activities of immunized rabbit serum
was tested by anti-MPO ELISA. The rabbit serum exhibited high
titer of anti-rat MPO activities by ELISA (Fig. 2A). To define the
reactive molecule, Western blotting analysis was performed after
SDS-PAGE (Fig. 2B). The results indicate that rabbit anti-rat
MPO antibodies react with 57 kD protein corresponding to the
a-subunit of rat MPO. Although the binding activity with the
f3-subunit was not demonstrated, it was shown that the serum
reacted with whole rat MPO molecules by Western blotting
analysis after SDS-PAGE under non-reducing conditions (data
not shown). The findings of the serum ANCA assay by immuno-
fluorescence have shown the fluorescence pattern, which is similar
to the so-called "P-ANCA" (Fig. 3). Notably, NRS has shown
significant binding to neither rat MPO nor rat PMN. In addition,
the result of indirect immunofluorescence microscopy using nor-
mal Wistar rat kidney frozen section revealed that rabbit anti-rat
MPO antiserum did not have any cross reactivities against renal
tissue antigens including cellular components.
Rat NTN
Rats receiving different doses of NTS were sacrificed at 3 or 15
hours after injection of NTS, then the severity of glomerulone-
phritis was evaluated histopathologically. Rats that received 0.2
ml of NTS showed mild glomerulonephritis, whereas rats that
received 0.5 or 0.7 ml of NTS showed severe glomerulonephritis
characterized by exudation of PMN at 3 hours and marked
glomerular fibrin deposition at 15 hours after injection of NTS.
Thus, 0.2 ml of NTS was used for the induction of NTN to study
in vivo effect of rabbit anti-rat MPO antibodies on rat NTN.
Effect of rabbit anti-rat MPO antibodies on rat NTN
Exacerbation of proteinuria. Rats developed proteinuria after
injection of NTS in group 1-c and group 2-c rats. The proteinuria
increased gradually from 142 71 mg on day 2 to 164 75 mg on
day 6 in group 1-c rats, whereas the proteinuria decreased from
127 63 mg on day 2 to 80 21 mg on day 6 in group 2-c rats
(Fig. 4). Although the proteinuria increased finally in both groups
of rats, the proteinuria in group 1-c rats was consistently higher
than that of group 2-c rats.
Aggravation of rat NTN by rabbit anti-rat MPO antibodies. Rats
were sacrificed at either 3 hours, 15 hours, or 14 days after
injection of NTS. By light microscopy, in group 1-a rats sacrificed
at 3 hours, predominant glomerular lesions were characterized by
exudation of PMN. However, in group 2-a rats, PMN exudation
was less prominent (Fig. 5 A,B). To determine the degree of PMN
infiltration in rats, numbers of PMN per glomerulus were counted.
In group 1-a rats, the PMN counts were significantly higher than
that of group 2-a rats (P < 0.01) (Fig. 6). In rats sacrificed at 15
hours, exudation and glomerular hypercellularity ceased, but
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Fig. 6. Counts of PMN in glomendi from group I-a and group 2-a rats. Results
are expressed as counts of PMN per glomerulus in a rat (mean 1 SD).
instead, a number of glomeruli showed intracapillary hyaline
thrombosis and marked dilatation or distortion of mesangial areas
in group 1-b rats, whereas hyaline thrombi were only found in a
few segmental glomerular tufts in group 2-b rats (Fig. 5 C, D). No
glomerular abnormalities were found in group 3 and group 4 rats.
In rats sacrificed at 14 days, although both groups of rats that
received NTS showed mild proliferative glomerulonephritis, there
were no significant histopathological differences in the two groups
of rats. Neither glomerular crescent formation nor tuft necrosis
was found in all groups of rats.
By immunofluorescence microscopy, in all groups of rats that
received NTS, strong linear binding of rabbit lgG was found along
capillary walls at 3 or 15 hours after NTS injection. There were no
significant differences between group 1 and group 2 rats, at least
at levels of immunofluorescence microscopy. A faint linear pat-
tern along capillary walls was found in rat C3, and rat IgG was
completely negative at 3 and 15 hours after injection of NTS. Mild
fibrin deposits were found in glomerular capillary lumens at 3
hours. In rats sacrificed at 15 hours, massive glomerular fibrin
deposits were observed in group 1-b rats in contrast to the mild
and segmental fibrin deposits in group 2-b rats (Fig. 7). Semi-
quantitative analysis of fibrin deposits revealed a marked differ-
ence of the fibrin score between the two groups of rats (group 1-b
rats, 131 8; and group 2-b rats, 27 21; P < 0.01; Fig. 8).
Thus, the rabbit anti-rat MPO antibodies clearly aggravated rat
NTN, yet the histopathology seen in group 1-a and 1-b rats was
not specific pathological changes but rather severe rat NTN.
Localization of MPO. In rats sacrificed at 3 hours, the MPO was
detected in interrupted pattern along the glomerular capillary
walls and in exudative leukocytes in group 1-a rats by immuno-
fluorescence microscopy. In group 2-a rats, the MPO was found in
only exudative leukocytes but in neither glomerular capillary walls
nor mesangial areas. At 15 hours, the presence of MPO in group
1-b rats became more intense as compared to that in group 1-a
rats; however, only very weak segmental deposition of MPO was
noted in group 2-b rats (Fig. 9 and Table 1). In rats sacrificed at
14 days after injection of NTS, rat MPO was almost negative in
glomeruli. In group 3 and group 4 rats, MPO was completely
negative in glomeruli.
Anti-rat MPO antibody activities in renal eluates. As MPO is
significantly detected in group 1-a rats at 3 hours and apparently
the deposition increased in group 1-b rats at 15 hours, it seemed
likely that administered rabbit anti-rat MPO antibodies actively
were involved in the enhanced deposition of MPO in group 1 rats.
On the mechanisms of MPO localization, renal elution studies
were performed to see if rabbit anti-rat MPO antibodies existed in
glomeruli, because it was extremely difficult to discriminate the
rabbit anti-rat MPO antibodies from the rabbit anti-rat GBM
antibodies on kidney sections. Rabbit anti-rat MPO antibody
activities were demonstrated in renal eluates obtained from the
kidneys of both group 1-a and 1-b rats by ELISA. Representative
results are shown in Figure 10. Stronger anti-MPO antibody
activities were noted in the eluate obtained from the kidneys of
group 1-b rats than in group 1-a rats by comparative titration assay
at same rabbit IgG levels (data not shown). The eluate obtained
from group 1-c rats did not show any anti-MPO antibody activi-
ties. In the eluates obtained from group 3 rats, no anti-MPO
antibody activities were detected. Notably, rabbit anti-rat GBM
antibody activities in eluates from group 1 and group 2 rats were
almost identical levels by indirect immunofluorescenee micros-
copy at any time sacrificed. In addition, there were no significant
differences in the amounts of eluted rabbit IgO per gram of kidneys
from group I and group 2 rats (5.0 1.5 jig; mean 1 SD).
Discussion
In the present study, we have shown that heterologous anti-rat
MPO antibodies clearly aggravated acute rat NTN by immuno-
pathological findings and exacerbation of proteinuria. The most
striking observation in the present study is the strong localization
of rat MPO in glomeruli from rats treated with both anti-MPO
antiserum and NTS (group 1 rats). In addition, anti-rat MPO
antibody activities were demonstrated in renal cluates from the
same groups of rats. These results indicate that anti-MPO anti-
bodies are clearly involved in the more severe glomerular lesions
via interactions with MPO itself or activation of PMN, which
release various kinds of mediators including MPO into the
extracellular microenvironment. Since administration of anti-
MPO antibodies alone was not able to induce any tissue lesions in
group 3 rats, the activation and degranulation of PMN are
prerequisites for the more severe pathological changes induced by
anti-rat MPO antibodies.
MPO is one of the lysosomal enzymes, which released from
PMN activated by various inflammatory stimuli [19]. Although the
primary action of MPO is a mierobicidal effect in the intraeellu-
larly, it could be involved in the tissue injury as a result of
generation of reactive oxygen radicals in extracellular milieu [19,
20].
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Fig. 7. Glomerular fibrin deposition in rats with
NTN. A. Marked fibrin deposition in a
glomerulus from a group 1-b rat (X400). B.
Minimal fibrin deposition in a glomerulus from
a group 2-b rat (x400).
a)00(I,
C
.0
U-
150
100
50
0
Group
Fig. 8. Semi-quantitative studies on glomendarfibrin deposits in group 1-b
and group 2-b rats. Results of fibrin deposits are expressed as a total of
fibrin score per rat (mean 1 SD).
Biochemically, it has been shown that MPO is able to bind to
anionic surfaces such as GBM or endothelial cells via its highly
cationic charge. Based on these characteristics, Johnson et al
demonstrated the development of glomerular injury induced by
MPO-hydrogen peroxide-halide system in vivo [211. Since it has
been well established that PMN play a major role in the develop-
ment of NTN especially at heterologous, that is, acute, phase [16,
22, 23], it is postulated that MPO is one of the significant enzymes
leading to glomerular pathological changes. In fact, it has been
reported that MPO could be detected enzymologically in renal
homogenates from rats with NTN [24].
In our experimental model, the effects of anti-rat MPO anti-
bodies on rat NTN were studied. Mild NTN was induced in rats to
see in vivo effect of anti-rat MPO antibodies by histopathological
studies and proteinuria. At the acute phase, rabbit anti-rat MPO
antibodies aggravated mild glomerulonephritis to severe acute
exudative glomerulonephritis. Since histopathological studies re-
vealed that pretreatment of anti-MPO antiserum promoted the
infiltration of PMN and enhanced fibrin deposition in glomeruli,
which are remarkable immunopathological features of acute rat
NTN, the involvement of anti-MPO antibodies is clearly indi-
cated. These histopathological changes could explain the exacer-
bation of proteinuria at the heterologous phase in rats with
anti-MPO pretreated NTN; that is, the course of proteinuria in
group 1 rats was apparently different from group 2 rats. The fact
that significantly higher amounts of proteinuria in group 1-C rats
was observed on day 6 could be ascribed to the continual
glomerular pathophysiological changes induced by anti-rat MPO
antibodies.
To analyze more directly the mechanisms of aggravation of
glomerulonephritis, the glomerular localization of MPO and the
presence of rabbit anti-rat MPO antibodies in glomeruli were
studied. Pre-treatment of anti-rat MPO antibodies could induce
or enhance the glomerular localization of MPO in rats with NTN.
As MPO is one of the lysosomal enzymes in PMN, it is most likely
that glomerular MPO would be released from PMN by the
cellular inflammatory reactions in NTN. Eventually the glomeru-
lar MPO localization, which may be a significant immunochemical
marker of acute and severe glomerular lesions, could be augu-
mented by anti-MPO antibodies. On the other hand, rabbit
anti-rat MPO antibodies could be eluted specifically from kidneys
in group 1 rats but not in group 3 rats. Therefore, the binding of
anti-rat MPO antibodies to MPO localized previously in glomeruli
is highly suggestive. The fact that anti-MPO antibody activities
were detected in renal eluates are quite significant, because it
indicates administered anti-MPO antibodies directly are involved
in the glomerular lesions in group 1 rats, whatever the mecha-
nisms may be. Further, the correlation of the intensity of glomer-
ular MPO deposition with the levels of eluted rabbit anti-rat MPO
antibodies also suggests the role of the anti-rat MPO antibodies.
However, it should be noted that there was no pathological
changes in group 3 and group 4 rats. Taken together, these results
indicate that interactions of MPO and anti-MPO antibodies are
P<0.01
1-b 2-b
Kobayashi et al: Anti-MPO antibodies and ON 461
Fig. 9. Localization of rat MPO in rats with
NTN Rat MPO was demonstrated by direct
immunofluorescence microscopy. A. Positive
staining for rat MPO along the glomerular
capillary walls and in leukocytes (group 1-a)(x400). B. Positive staining for rat MPO is seen
only in leukocytes. Note the absence of rat
MPO staining along the glomerular capillary
walls (group 2-a) (X400). C. Strong positive
staining for rat MPO both along the capillary
walls and in mesangial areas (group 1-b)
(x400). D. Very weak staining for rat MPO is
seen in segmental glomerular tufts (group 2-b)
(x400).
Rats N'
MPO in glomeruli
+ ++
Group 1-b 6 0/6 0/6 4/6 2/6
Group 2-b 6 3/6 2/6 1/6 0/6
Group 3 6 6/6 0/6 0/6 0/6
Group 4 6 6/6 0/6 0/6 0/6
critical events leading to more severe glomerular lesions in group
1 rats than group 2 rats.
Several mechanisms responsible for the aggravation of rat NTN
may be considered. First, a possible mechanism is the formation
of MPO-anti-MPO antibodies complexes in glomeruli. These
complexes would promote the enhanced PMN infiltration and
fibrin deposition in group 1 rats. In fact, Brouwer et al reported an
experimental model developing acute necrotizing CGN as a result
of the interaction between a human MPO-directed immune
response and the lysosomal enzyme extract plus H202, which were
infused from renal artery in human MPO immunized Brown-
Norway rats [25]. Second, the prolongation of MPO enzyme
activities by the binding of antibodies may be considered, as in the
case of a recent observation on the inhibition of PR3 complex-
ation with alpha 1-antitrypsin, the major inhibitor of PR3 by
C-ANCA [261. Consequently, it will activate the MPO-hydrogen
peroxide-halide system which generates hypochlorous acid
Table 1. Presence of rat MPO in kidneys from rats with NTN
Incidence of positive MPO staining
b Intensity of MPO staining was semi-quantitated by direct immunoflu-
orescence microscopy
C Number of rats studied
1.0
0.8
0.6
a
o 0.4
0.2
0.0
1000
Eluted rabbit IgG, ng/ml
Fig. 10. Rabbit anti-rat MPO antibody activities in renal eluates obtained
from group 1-b (.) and 2-b (0) rats. Results are expressed as OD at 405 mn.
1 10 100
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(HOC!). Thus, the hypochiorous acid or a similar oxidant gener-
ated by the stimulated PMN would p!ay a critical role in GBM
degradation [201. Alternatively, the direct activation of PMN by
anti-MPO antibodies should be considered. Recently, Falk et a!
reported that anti-MPO antibodies stimulate PMN in vitro and
induce the generation of reactive oxygen radicals as well as
degranulation [61. In our model, PMN activated by the inflamma-
tory process of rat NTN may be activated further by anti-rat MPO
antibodies in circulation or in situ. Consequently, this would
enhance glomerular MPO deposition associated with anti-rat
MPO antibodies, one of the inflammatory mediators, which
aggravate the rat NTN. Obviously, activated PMN releases vari-
ous kinds of mediators, for example, lysosomal enzymes such as
neutral proteinases, which degrade human GBM in vitro [27, 28].
Therefore, MPO may be only one of the enzymes participating in
the glomerular injury.
In our experimental condition, neither glomerular crescent
formation nor tuft necrosis has been observed in group 1 rats,
despite the aggravation of the histopathology. This might be partly
ascribable to certain genetic factors that determine cellular im-
munological response in rats. Indeed, it has been known that the
Wistar rat is not highly susceptible to the crescent formation, in
contrast to the susceptibility to crescentic NTN in the strain of
WKY rat [29].
It should be emphasized that our aim in this study was to
investigate the effects of anti-MPO antibodies on PMN mediated
glomerular injury. For that purpose, we injected a small dose of
NTS to induce mild NTN. Accordingly, our experimental model
may not be analogous to human ANCA related glomerulonephri-
tis characterized by the paucity of visible immune deposits,
although the co-existence of both ANCA and anti-GBM antibod-
ies, which significance is still uncertain, has been recently reported
in anti-GBM mediated glomerulonephritis [30—33]. Nevertheless,
the data presented here strongly suggest that MPO-ANCA may
be actively involved in the glomerular pathology, not solely but in
concert with the pre-existence of activated PMN. This is of clinical
importance, because it has been obserbed intercurrent infections,
resulting in priming of PMN, frequently precede disease activity
[34]. Falk et al has also reported that in the majority of patients,
flu-like prodrome occurred prior to the onset of overt ANCA
associated diseases [4, 35].
At present, the pathogenic role of anti-MPO antibodies for
ANCA associated glomerulonephritis and vasculitis, remains un-
proven. Several lines of evidence support the hypothesis that
ANCA and its target antigens may be implicated in the pathogen-
esis of these diseases [4, 5, 36, 37]. In the present study, we have
demonstrated that anti-rat MPO antibodies potentially are in-
volved in the glomerular injury when they will interact MPO
molecules. Although, the in vitro effects of the rabbit anti-rat
MPO antibodies on enzyme activities or PMN function remain to
be determined, our results using an animal model suggest patho-
genic significance of anti-MPO antibodies in human ANCA-
associated diseases.
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Appendix. Abbreviations
anti-neutrophil cytoplasmic antibody(ies)
crescentic glomerulonephritis
enzyme-linked immunosorbent assay
glomerular basement membrane
myeloperoxidase
normal rabbit serum
nephrotoxic serum nephritis
nephrotoxic serum
polymorphonuclear leukocyte(s)
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